NASDAQ: AGTC |
| Healthcare / Biotechnology / USA |
0.7350 | +0.1180 | +19.12% | Vol 331.10K | 1Y Perf -85.02% |
Jun 27th, 2022 16:00 DELAYED |
BID | 0.7200 | ASK | 0.7400 | ||
Open | 0.7252 | Previous Close | 0.6170 | ||
Pre-Market | - | After-Market | 0.74 | ||
- - | 0.00 0.54% |
Target Price | 10.40 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 1.31K | Finscreener Ranking | ★★ 45.77 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★ 39.49 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★ 34.74 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 3.87 | Earnings Rating | Strong Buy | |
Market Cap | 37.29M | Earnings Date | 16th May 2022 | |
Alpha | -0.02 | Standard Deviation | 0.22 | |
Beta | 1.65 |
Today's Price Range 0.70000.7500 | 52W Range 0.58004.59 | 5 Year PE Ratio Range -47.00575.00 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -9.93% | ||
1 Month | -12.51% | ||
3 Months | -35.53% | ||
6 Months | -60.70% | ||
1 Year | -85.02% | ||
3 Years | -80.61% | ||
5 Years | -85.87% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -22.23 | |||
ROE last 12 Months | -90.45 | |||
ROA (5Y Avg) | -18.94 | |||
ROA last 12 Months | -59.81 | |||
ROC (5Y Avg) | -9.75 | |||
ROC last 12 Months | -65.79 | |||
Return on invested Capital Q | -18.45 | |||
Return on invested Capital Y | -10.55 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 5.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.40 | ||||
0.67 | ||||
74.58 | ||||
1.80 | ||||
-0.50 | ||||
-1.42 | ||||
0.67 | ||||
0.93 | ||||
-11 987 400.00 | ||||
Forward PE | -0.64 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.60 | ||||
2.70 | ||||
0.23 | ||||
0.52 | ||||
-24.70 | ||||
Leverage Ratio | 1.60 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-12 441.20 | ||||
-12 147.80 | ||||
-390.70 | ||||
-80.91 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
500.00K | ||||
0.01 | ||||
-77.11 | ||||
-62.39 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2022 | -0.42 | -0.33 | 21.43 |
Q02 2022 | -0.38 | -0.45 | -18.42 |
Q01 2022 | -0.35 | -0.40 | -14.29 |
Q04 2021 | -0.37 | -0.28 | 24.32 |
Q03 2021 | -0.41 | -0.40 | 2.44 |
Q02 2021 | -0.59 | -0.60 | -1.69 |
Q01 2021 | -0.51 | -0.60 | -17.65 |
Q04 2020 | -0.46 | -0.56 | -21.74 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.27 | 30.77 | Positive |
6/2022 FY | -1.44 | 13.25 | Positive |
9/2022 QR | -0.25 | 48.98 | Positive |
6/2023 FY | -0.95 | 23.39 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.42 |
Estimates Count | 4 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 331.10K |
Shares Outstanding | 50.73K |
Shares Float | 50.60M |
Trades Count | 1.61K |
Dollar Volume | 242.37K |
Avg. Volume | 375.44K |
Avg. Weekly Volume | 401.77K |
Avg. Monthly Volume | 242.14K |
Avg. Quarterly Volume | 482.42K |
Applied Genetic Technologies Corporation (NASDAQ: AGTC) stock closed at 0.735 per share at the end of the most recent trading day (a 19.12% change compared to the prior day closing price) with a volume of 331.10K shares and market capitalization of 37.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 83 people. Applied Genetic Technologies Corporation CEO is Susan B. Washer.
The one-year performance of Applied Genetic Technologies Corporation stock is -85.02%, while year-to-date (YTD) performance is -61.32%. AGTC stock has a five-year performance of -85.87%. Its 52-week range is between 0.58 and 4.59, which gives AGTC stock a 52-week price range ratio of 3.87%
Applied Genetic Technologies Corporation currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.67, a price-to-sale (PS) ratio of 74.58, a price to cashflow ratio of 1.80, a PEG ratio of 2.32, a ROA of -59.81%, a ROC of -65.79% and a ROE of -90.45%. The company’s profit margin is -80.91%, its EBITDA margin is -12 147.80%, and its revenue ttm is $500.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from Applied Genetic Technologies Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Applied Genetic Technologies Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Applied Genetic Technologies Corporation is Strong Buy (1), with a target price of $10.4, which is +1 314.97% compared to the current price. The earnings rating for Applied Genetic Technologies Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Applied Genetic Technologies Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Applied Genetic Technologies Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 14.93, ATR14 : 0.09, CCI20 : -231.52, Chaikin Money Flow : -0.11, MACD : -0.04, Money Flow Index : 47.52, ROC : -32.20, RSI : 28.33, STOCH (14,3) : 10.00, STOCH RSI : 0.00, UO : 40.88, Williams %R : -90.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Applied Genetic Technologies Corporation in the last 12-months were: Gerald Anthony Reynolds (Sold 3 994 shares of value $3 376 ), Susan B. Washer (Option Excercise at a value of $55 810), Susan B. Washer (Sold 9 950 shares of value $21 691 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
CEO: Susan B. Washer
Telephone: +1 386 462-2204
Address: 14193 NW 119th Terrace, Alachua 32615, FL, US
Number of employees: 83
Thu, 19 May 2022 08:05 GMT Analysts Are Bullish on These Healthcare Stocks: Applied Genetic Technologies (AGTC), Mersana Therapeutics (MRSN)
- TipRanks. All rights reserved.Mon, 14 Feb 2022 16:50 GMT Applied Genetic Technologies (AGTC) Gets a Buy Rating from H.C. Wainwright
- TipRanks. All rights reserved.Fri, 14 Jan 2022 09:11 GMT Applied Genetic Technologies (AGTC) Receives a Buy from Wells Fargo
- TipRanks. All rights reserved.Tue, 11 Jan 2022 16:05 GMT Applied Genetic Technologies (AGTC) Receives a Buy from H.C. Wainwright
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.